Ono Pharmaceutical Co., Ltd. (TYO:4528)
2,312.50
+8.00 (0.35%)
Apr 28, 2026, 3:30 PM JST
Ono Pharmaceutical Revenue
Ono Pharmaceutical had revenue of 139.90B JPY in the quarter ending December 31, 2025, with 4.23% growth. This brings the company's revenue in the last twelve months to 509.35B, up 4.52% year-over-year. In the fiscal year ending March 31, 2025, Ono Pharmaceutical had annual revenue of 486.87B, down -3.14%.
Revenue (ttm)
509.35B
Revenue Growth
+4.52%
P/S Ratio
2.13
Revenue / Employee
118.81M
Employees
4,287
Market Cap
1.09T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 486.87B | -15.80B | -3.14% |
| Mar 31, 2024 | 502.67B | 55.49B | 12.41% |
| Mar 31, 2023 | 447.19B | 85.83B | 23.75% |
| Mar 31, 2022 | 361.36B | 52.08B | 16.84% |
| Mar 31, 2021 | 309.28B | 16.86B | 5.77% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Otsuka Holdings | 2.47T |
| Astellas Pharma | 2.06T |
| Daiichi Sankyo Company | 2.05T |
| Chugai Pharmaceutical | 1.29T |
| Kyowa Kirin | 496.83B |
| Santen Pharmaceutical | 287.99B |
| JCR Pharmaceuticals | 37.55B |
| Perseus Proteomics | 140.41M |
Ono Pharmaceutical News
- 6 days ago - Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight - Business Upturn
- 6 days ago - Ono Pharma Announces Upcoming Presentations at the ASCO 2026 Annual Meeting - Business Wire
- 4 weeks ago - Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan - Business Wire
- 2 months ago - Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology - Business Wire
- 2 months ago - Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL - Business Wire
- 3 months ago - Ono Pharmaceutical Transcript: 44th Annual J.P. Morgan Healthcare Conference - Transcripts
- 3 months ago - Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical - GlobeNewsWire
- 5 months ago - Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting - Business Wire